Difference between revisions of "CD138"

From Libre Pathology
Jump to navigation Jump to search
Line 1: Line 1:
'''CD138''', also known as '''Syndecan-1''', is an [[immunostain]] that marks [[plasma cells]].
'''CD138''', also known as '''Syndecan-1''' (abbreviated '''SDC1'''),<ref name=omim186355>{{OMIM|186355}}</ref> is an [[immunostain]] that marks [[plasma cells]].
 
It plays a role in angiogenesis and cellular proliferation.<ref name=pmid26513873>{{Cite journal  | last1 = Guo | first1 = Q. | last2 = Yang | first2 = X. | last3 = Ma | first3 = Y. | last4 = Ma | first4 = L. | title = Syndecan-1 serves as a marker for the progression of epithelial ovarian carcinoma. | journal = Eur J Gynaecol Oncol | volume = 36 | issue = 5 | pages = 506-13 | month =  | year = 2015 | doi =  | PMID = 26513873 }}</ref>


==Positive==
==Positive==

Revision as of 14:41, 8 December 2015

CD138, also known as Syndecan-1 (abbreviated SDC1),[1] is an immunostain that marks plasma cells.

It plays a role in angiogenesis and cellular proliferation.[2]

Positive

See also

References

  1. Online 'Mendelian Inheritance in Man' (OMIM) 186355
  2. Guo, Q.; Yang, X.; Ma, Y.; Ma, L. (2015). "Syndecan-1 serves as a marker for the progression of epithelial ovarian carcinoma.". Eur J Gynaecol Oncol 36 (5): 506-13. PMID 26513873.
  3. Humphrey, Peter A; Dehner, Louis P; Pfeifer, John D (2008). The Washington Manual of Surgical Pathology (1st ed.). Lippincott Williams & Wilkins. pp. 554. ISBN 978-0781765275.
  4. Lim, GH.; Tan, PH.; Jara-Lazaro, AR.; Thike, AA.; Sim, WC.; Yap, VB.; Yip, GW. (Sep 2014). "Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival.". Singapore Med J 55 (9): 468-72. PMID 25273930.
  5. Zhang, W.; Jiang, YX.; Liu, Y.; Yu, WJ.; Zhao, H.; Li, YJ. (Jul 2013). "[Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic study of 16 cases].". Zhonghua Bing Li Xue Za Zhi 42 (7): 433-7. PMID 24246859.

.